Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects

• Published in: Clinical drug investigation Vol. 42; no. 5; pp. 447 - 458
• Main Authors: Xiang, Qian, Liu, Zhiyan, Mu, Guangyan, Xie, Qiufen, Zhang, Hanxu, Zhou, Shuang, Wang, Zining, Guo, Ninghong, Huang, Jie, Jiang, Jie, Li, Jian, Yang, Guoping, Cui, Yimin
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.05.2022; Springer Nature B.V
• Subjects: Adenosine; Adenosine diphosphate; Bioequivalence; Bioinformatics; Blood platelets; Cell Adhesion Molecules; Clinical trials; Drug development; Drug dosages; Gene loci; Genome-Wide Association Study; Humans; Internal Medicine; Intracellular Signaling Peptides and Proteins - pharmacology; Ion Channels; Lectins, C-Type; Medicine; Medicine & Public Health; NCT; NCT03161002; Nuclear Pore Complex Proteins - pharmacology; Nucleotides - pharmacology; Original Research Article; Pharmacodynamics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Platelet Aggregation; Platelet Aggregation Inhibitors; Poly(ADP-ribose) Polymerases - pharmacology; Polymorphism; Polymorphism, Single Nucleotide - genetics; Protein Serine-Threonine Kinases - antagonists & inhibitors; Proto-Oncogene Proteins; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Beijing China; United States > US; China

Background and Objective The search for potential gene loci that affect the pharmacodynamics and pharmacokinetics of ticagrelor is a matter of broad clinical interest. The objective of this study was to investigate the effect of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of t...